Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock - $0.001 par value
Symbol
CTKB on Nasdaq
Shares outstanding
127,940,509
Price per share
$5.01
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
81,628,344
Total reported value
$412,223,756
% of total 13F portfolios
0%
Share change
+1,831,914
Value change
+$10,880,321
Number of holders
152
Price from insider filings
$5.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13% -8.6% $56,208,317 -$6,633,186 16,531,858 -11% BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 6.1% -17% $26,401,469 -$6,313,358 7,765,138 -19% The Vanguard Group 30 Jun 2025
Topline Capital Management, LLC 5.3% $28,140,515 6,780,847 Topline Capital Management, LLC 25 Sep 2025
BROWN CAPITAL MANAGEMENT LLC 3.9% -33% $17,204,316 -$8,695,650 4,958,016 -34% Brown Capital Management, LLC 30 Sep 2025

As of 31 Dec 2025, 152 institutional investors reported holding 81,628,344 shares of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB). This represents 64% of the company’s total 127,940,509 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 17,173,028 +3.8% 0% $86,723,792
VANGUARD GROUP INC 5.8% 7,475,477 +7.8% 0% $37,751,160
Topline Capital Management, LLC 5.8% 7,442,466 +7.2% 3.4% $37,584,453
HHLR ADVISORS, LTD. 5.2% 6,657,030 0% 1.1% $33,618,002
Boston Partners 3.9% 5,008,309 +13369% 0.03% $25,297,227
MILLENNIUM MANAGEMENT LLC 3.7% 4,752,447 +39% 0.02% $23,999,857
STATE STREET CORP 3.2% 4,146,964 +1.5% 0% $20,942,168
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,790,574 +0.26% 0% $14,095,696
DIMENSIONAL FUND ADVISORS LP 2.1% 2,646,891 -18% 0% $13,366,732
BROWN CAPITAL MANAGEMENT LLC 1.6% 2,072,915 -58% 0.86% $10,468,221
GOLDMAN SACHS GROUP INC 1.4% 1,789,914 +3% 0% $9,039,066
MORGAN STANLEY 1.3% 1,700,985 +16% 0% $8,589,975
ROYCE & ASSOCIATES LP 1.3% 1,692,657 -4% 0.09% $8,547,918
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.86% 1,094,539 -0.95% 0% $5,527,422
Russell Investments Group, Ltd. 0.78% 1,001,127 +528% 0.01% $5,055,684
NORTHERN TRUST CORP 0.75% 957,594 -5.5% 0% $4,835,850
BANK OF AMERICA CORP /DE/ 0.67% 856,161 +403% 0% $4,323,612
WELLINGTON MANAGEMENT GROUP LLP 0.6% 764,279 -70% 0% $3,859,609
AQR CAPITAL MANAGEMENT LLC 0.58% 743,455 -27% 0% $3,754,447
RENAISSANCE TECHNOLOGIES LLC 0.53% 675,000 -15% 0.01% $3,408,750
ACADIAN ASSET MANAGEMENT LLC 0.53% 674,475 +19% 0.01% $3,402,000
PRINCIPAL FINANCIAL GROUP INC 0.52% 666,927 +7% 0% $3,367,982
Bank of New York Mellon Corp 0.5% 637,929 -5.3% 0% $3,221,542
UBS Group AG 0.36% 460,047 -1.8% 0% $2,323,238
HRT FINANCIAL LP 0.34% 437,653 0.01% $2,210,000

Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 81,628,344 $412,223,756 +$10,880,321 $5.05 152
2025 Q3 79,957,211 $277,468,446 +$1,963,995 $3.47 151
2025 Q2 79,443,660 $270,126,999 +$5,595,600 $3.40 156
2025 Q1 77,562,435 $311,007,504 -$4,129,971 $4.01 159
2024 Q4 77,254,066 $501,381,338 +$11,940,410 $6.49 150
2024 Q3 74,960,438 $415,264,156 -$14,542,700 $5.54 134
2024 Q2 76,158,342 $424,969,676 -$33,289,478 $5.58 126
2024 Q1 80,524,601 $540,295,292 +$11,110,651 $6.71 119
2023 Q4 78,933,920 $719,883,797 +$17,961,713 $9.12 101
2023 Q3 77,486,686 $427,726,918 -$3,527,385 $5.52 106
2023 Q2 77,036,054 $657,934,234 +$69,958,551 $8.54 100
2023 Q1 68,508,151 $629,603,408 +$39,123,355 $9.19 100
2022 Q4 64,201,674 $655,512,030 +$29,671,547 $10.21 100
2022 Q3 61,170,760 $900,430,367 +$128,781,199 $14.72 87
2022 Q2 52,912,941 $567,776,021 +$56,303,644 $10.73 81
2022 Q1 47,712,980 $514,520,453 +$122,459,757 $10.78 72
2021 Q4 35,038,930 $571,924,873 -$4,872,187 $16.32 51
2021 Q3 34,351,929 $744,420,532 +$744,420,530 $21.41 53